Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2016 07:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference

NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV)...
April 13, 2016 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials

—In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties— —Planning to Start Phase 1...
March 30, 2016 07:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016

BARCELONA, Spain and NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for...
February 19, 2016 07:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Webcast Upcoming Investor Conferences

INDIANAPOLIS, Feb. 19, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut...
January 27, 2016 07:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technology Achieves Targeted Delivery to the Lower GI Tract

PHILADELPHIA and INDIANAPOLIS, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing treatments for infectious diseases including hepatitis B...
January 11, 2016 07:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Expands Senior Leadership Team

INDIANAPOLIS, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus...
December 21, 2015 07:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Appoints Biotech Veteran Alan J. Lewis to Board of Directors

INDIANAPOLIS, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus...
December 16, 2015 07:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present at Jefferies Microbiome Summit

INDIANAPOLIS, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus...
December 09, 2015 07:00 ET | Source: Assembly Biosciences, Inc.

Clinical Study Shows Assembly Biosciences' Oral Gemicel™ Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications

—Assembly is Developing Curative Treatments for HBV, Resistant C. difficile Infections (CDI) and Other Infectious Diseases— —Expects to Initiate Phase lb Trial in 2016 Using Gemicel to Deliver...
October 06, 2015 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting

—Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies— —Assembly Also...